Table of Contents
- Clinical trial overview
- Main studies and who they include
- What the trials measure
- Trial phases and study design
- Patient-friendly terms
- Key points from the trial data
Clinical trial overview
These clinical trials are testing IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D in people with multiple myeloma.[1] The studies include both newly diagnosed multiple myeloma and relapsed or refractory multiple myeloma.[1][2][3] All listed trials are interventional, which means researchers assign treatment and then measure the results.[1][2][3]
Main studies and who they include
One Phase 2 study, NCT06189833, is authorised and includes 237 participants with newly diagnosed multiple myeloma.[1] Its brief summary says the study compares minimal residual disease, or MRD, using different testing methods at key time points across several cohorts.[1] A cohort is a group of participants in a study who are followed in a similar way.[1]
A second Phase 2 study, 2025-521976-80-00, is authorised and includes 131 participants with relapsed or refractory multiple myeloma.[2] This study is designed to evaluate the efficacy of IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D.[2] Efficacy means how well a treatment works.[2]
A Phase 3 study, 2025-522007-18-00, is authorised and includes 307 participants with relapsed or refractory multiple myeloma.[3] This study compares IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D with an anti-BCMAxCD3 bispecific antibody, which is a different treatment approach used as the comparison group.[3]
What the trials measure
The NCT06189833 study looks at MRD measurements by NGS in bone marrow and by MS in blood protein samples at key time points.[1] NGS, or next-generation sequencing, is a very sensitive lab method, and MS means mass spectrometry, another detailed testing method.[1] These tests help researchers see how much disease may remain after treatment.[1]
The 2025-521976-80-00 study has overall response rate as its primary outcome.[2] This tells researchers how many participants have a meaningful reduction in their cancer after treatment.[2]
The 2025-522007-18-00 study has dual primary endpoints: overall response rate and progression-free survival.[3] Progression-free survival means the time during which the disease does not get worse.[3]
Trial phases and study design
The trial data show two Phase 2 studies and one Phase 3 study.[1][2][3] Phase 2 studies usually look more closely at whether a treatment works, while Phase 3 studies compare treatments in larger groups.[2][3]
All three studies are listed as authorised, meaning they have approval to run in the listed setting.[1][2][3] The study records also show different treatment settings, including combination treatment and direct comparison with another bispecific antibody.[1][3]
Patient-friendly terms
Multiple myeloma is a cancer of plasma cells, which are white blood cells found in the bone marrow.[1][2][3]
Newly diagnosed means the disease has been found recently.[1]
Relapsed means the disease came back after treatment, and refractory means it did not respond well to treatment.[2][3]
Primary outcome is the main result the researchers want to measure.[2][3]
Bone marrow is the soft tissue inside bones where blood cells are made.[1]
Key points from the trial data
The trial program is focused on multiple myeloma and includes both earlier and later phases of testing.[1][2][3] The studies are designed to learn how well IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D performs in different patient groups and treatment settings.[1][2][3] The key measures are MRD testing, overall response rate, and progression-free survival.[1][2][3]
